| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CN Healthy Food Tech Group Corp. Common Stock$5.51
+0.21 (+3.96%)
Market Cap
287.81 M
EPS
0.10
P/E Ratio
56.05 $
Value Trade
38.81 M
SEC Financials
Q1 2026Dilution Risk
Revenue
5.83 M
R&D Expenses
38.37 K
Operating CF
-3.60 M
Total Assets
39.12 M
Total Liabilities
19.22 M
Equity
19.90 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
29.69 M
Monthly Burn
1.20 M
Runway
23.5 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
5.44 M
52 Week Range
3.41 - 14.71
% held by Insiders
-
% held by Institutions
-
Enterprise Value
258.75 M
Total Shares
52.23 M
Short %
4.94 %
Float Shares
4.54 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in UCFI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CN Healthy Food Tech Group Corp. Common Stock (UCFI) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
UCFI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
UCFI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
UCFI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
UCFI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
UCFI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-UCFI
Oct 6, 2025ZHONG GUO LIANG TOU GROUP LIMITED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024 ZHONG GUO LIANG TOU GROUP LIMITED INDE
Zhong Guo Liang Tou Group Limited has released its unaudited consolidated financial statements for the periods ending June 30, 2025, and December 31, 2024. The company reported significant growth in revenue and gross profit, with a net income of approximately $2.92 million for the second quarter of 2025, compared to $356,838 for the same period in 2024. Total assets rose slightly, while liabilities decreased, leading to improved stockholder equity. These results reflect the company's strong performance in the health and wellness food industry.
Read more →-UCFI
Jun 4, 2025IRON HORSE ACQUISITIONS POSTPONES BUSINESS COMBINATION SPECIAL MEETING UNTIL JUNE 20, 2025 extends redemption date in connection with business combination meeting from june 6, 2025 to june 18, 2025 clarifies redemption p
Iron Horse Acquisitions Corp. has postponed its Special Meeting for a proposed business combination with Rosy Sea Holdings Limited and Zhong Guo Liang Tou Group Limited, moving it from June 10, 2025, to June 20, 2025. Alongside this, the deadline for public stockholders to redeem their shares has been extended from June 6, 2025, to June 18, 2025. The meetings will also involve discussions on charter extensions and the redemption process for shareholders. Iron Horse emphasizes the importance of timely communication regarding these changes for affected shareholders.
Read more →-UCFI
Oct 2, 2024IRON HORSE ACQUISITIONS ANNOUNCES BUSINESS COMBINATION AGREEMENT WITH PARENT OF Zhong Guo Liang Tou Group Limited (d/b/a china food investment) TOLUCA LAKE, CALIFORNIA, USA and
Iron Horse Acquisitions Corp. (UCFI) has announced a business combination agreement with Rosey Sea Holdings Limited, the parent company of Zhong Guo Liang Tou Group Limited (doing business as China Food Investment). This acquisition aims to bring CFI under the Iron Horse umbrella, allowing it to focus on health and agricultural biotechnology products. If completed, this merger will position the combined company for substantial growth in the health food sector, with an estimated enterprise value of $523 million. The transaction is slated to close in early 2025, pending regulatory approvals.
Read more →-UCFI
Dec 29, 2023Iron Horse Acquisitions Corp. INDEX TO FINANCIAL STATEMENT Page Audited Balance Sheet of Iron Horse Acquisitions Corp.: Report of Independent Registered Public Accounting Firm (PCAOB ID 206) F-2 Balance Sheet as of
Iron Horse Acquisitions Corp. has released its audited balance sheet as of December 29, 2023. The independent auditor expressed an opinion that the financial statement fairly represents the company’s financial position according to generally accepted accounting principles. However, the report highlights a significant concern regarding the company's ability to remain operational due to a net capital deficiency and dependence on completing a business combination. Without this, the company may be forced to liquidate its operations. The statement reflects the company’s precarious financial condition as it transitions from formation to potential operation.
Read more →-UCFI
Dec 27, 2023Iron Horse Acquisitions Corp. Announces Pricing of $61,000,000 Initial Public Offering Toluca Lake, CA
Iron Horse Acquisitions Corp. has announced the pricing of its initial public offering (IPO) for $61,000,000, consisting of 6,100,000 units priced at $10.00 each. The units will trade on the Nasdaq under the ticker symbol 'IROHU' starting from December 27, 2023. Each unit includes one share of common stock, one warrant, and a right to receive one-fifth of a share upon a business combination. The offering is expected to close on December 28, 2023, pending customary closing conditions.
Read more →Competitive Position
How UCFI ranks across every disease it competes inCompetitive Position is a premium feature
See how UCFI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial